Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H26F3N3OS.2C4H4O4 |
Molecular Weight | 669.666 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 2 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.OCCN1CCN(CCCN2C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1
InChI
InChIKey=GTJLCONXCUYJOF-SPIKMXEPSA-N
InChI=1S/C22H26F3N3OS.2C4H4O4/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;2*5-3(6)1-2-4(7)8/h1-2,4-7,16,29H,3,8-15H2;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1-
DescriptionSources: http://www.drugbank.ca/drugs/DB00623Curator's Comment: Description was created based on several sources, including
Sources: http://www.drugbank.ca/drugs/DB00623
Curator's Comment: Description was created based on several sources, including
Fluphenazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Fluphenazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. Fluphenazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
CNS Activity
Originator
Sources: http://adisinsight.springer.com/drugs/800002142
Curator's Comment: Introduced in 1959
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3383 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9755905 |
|||
Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00623 |
|||
Target ID: CHEMBL225 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11561066 |
1.412 µM [EC50] | ||
Target ID: CHEMBL1907610 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2879204 |
|||
Target ID: CHEMBL2056 Sources: http://www.drugbank.ca/drugs/DB00623 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FLUPHENAZINE DECANOATE Approved UseFluphenazine Decanoate Injection is a longacting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Launch Date1987 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.3 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8911886 |
12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUPHENAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
261 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8911886 |
2.5 mg 3 times / 3 days multiple, intravenous dose: 2.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
FLUPHENAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
0.52 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2313572 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUPHENAZINE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.92 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2313572 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUPHENAZINE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.4 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8911886 |
12 mg single, oral dose: 12 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUPHENAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
12.3 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8911886 |
2.5 mg 3 times / 3 days multiple, intravenous dose: 2.5 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
FLUPHENAZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
13 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2313572 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
FLUPHENAZINE plasma | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.6% |
FLUPHENAZINE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
21 mg 1 times / day multiple, intramuscular (max) Recommended Dose: 21 mg, 1 times / day Route: intramuscular Route: multiple Dose: 21 mg, 1 times / day Sources: Page: p.315 |
unhealthy, 35.4+/-10.4 n = 30 Health Status: unhealthy Condition: Schizophrenia Age Group: 35.4+/-10.4 Sex: M+F Population Size: 30 Sources: Page: p.315 |
Disc. AE: Akathisia, Dyskinesia... AEs leading to discontinuation/dose reduction: Akathisia (3.3%) Sources: Page: p.315Dyskinesia (3.3%) Hypertonia (3.3%) Stupor (3.3%) |
250 mg 1 times / week multiple, intramuscular Highest studied dose Dose: 250 mg, 1 times / week Route: intramuscular Route: multiple Dose: 250 mg, 1 times / week Sources: Page: p.1438 |
unhealthy, 44 n = 25 Health Status: unhealthy Condition: Schizophrenia Age Group: 44 Sex: M+F Population Size: 25 Sources: Page: p.1438 |
|
100 mg single, intramuscular|subcutaneous Recommended Dose: 100 mg Route: intramuscular|subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: |
Disc. AE: Tardive dyskinesia, Neuroleptic malignant syndrome... AEs leading to discontinuation/dose reduction: Tardive dyskinesia Sources: Neuroleptic malignant syndrome Fall |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Akathisia | 3.3% Disc. AE |
21 mg 1 times / day multiple, intramuscular (max) Recommended Dose: 21 mg, 1 times / day Route: intramuscular Route: multiple Dose: 21 mg, 1 times / day Sources: Page: p.315 |
unhealthy, 35.4+/-10.4 n = 30 Health Status: unhealthy Condition: Schizophrenia Age Group: 35.4+/-10.4 Sex: M+F Population Size: 30 Sources: Page: p.315 |
Dyskinesia | 3.3% Disc. AE |
21 mg 1 times / day multiple, intramuscular (max) Recommended Dose: 21 mg, 1 times / day Route: intramuscular Route: multiple Dose: 21 mg, 1 times / day Sources: Page: p.315 |
unhealthy, 35.4+/-10.4 n = 30 Health Status: unhealthy Condition: Schizophrenia Age Group: 35.4+/-10.4 Sex: M+F Population Size: 30 Sources: Page: p.315 |
Hypertonia | 3.3% Disc. AE |
21 mg 1 times / day multiple, intramuscular (max) Recommended Dose: 21 mg, 1 times / day Route: intramuscular Route: multiple Dose: 21 mg, 1 times / day Sources: Page: p.315 |
unhealthy, 35.4+/-10.4 n = 30 Health Status: unhealthy Condition: Schizophrenia Age Group: 35.4+/-10.4 Sex: M+F Population Size: 30 Sources: Page: p.315 |
Stupor | 3.3% Disc. AE |
21 mg 1 times / day multiple, intramuscular (max) Recommended Dose: 21 mg, 1 times / day Route: intramuscular Route: multiple Dose: 21 mg, 1 times / day Sources: Page: p.315 |
unhealthy, 35.4+/-10.4 n = 30 Health Status: unhealthy Condition: Schizophrenia Age Group: 35.4+/-10.4 Sex: M+F Population Size: 30 Sources: Page: p.315 |
Fall | Disc. AE | 100 mg single, intramuscular|subcutaneous Recommended Dose: 100 mg Route: intramuscular|subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: |
Neuroleptic malignant syndrome | Disc. AE | 100 mg single, intramuscular|subcutaneous Recommended Dose: 100 mg Route: intramuscular|subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: |
Tardive dyskinesia | Disc. AE | 100 mg single, intramuscular|subcutaneous Recommended Dose: 100 mg Route: intramuscular|subcutaneous Route: single Dose: 100 mg Sources: |
unhealthy Health Status: unhealthy Condition: Schizophrenia Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
moderate [Ki 40.2 uM] | ||||
Page: 5.0 |
weak [IC50 398.1 uM] | |||
Page: 5.0 |
weak [IC50 441.2 uM] | |||
yes [Ki 9.4 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/23395964/ Page: 7.0 |
PubMed
Title | Date | PubMed |
---|---|---|
[Psuedotetanus caused by neuroleptics. Description of a case caused by fluphenazine]. | 1966 Sep-Oct |
|
Drug-induced extrapyramidal symptoms: their incidence and treatment. | 1967 Jan |
|
Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy. | 1975 Jan-Feb |
|
Schizophrenia-like reaction to diethylpropion. | 1976 Nov 27 |
|
Dystonic reaction to high dose propranolol. | 1977 Oct 29 |
|
Sleep disturbance associated with fluphenazine HCl: a case report. | 1979 Jul |
|
Neuroleptic-induced seizures. An in vitro technique for assessing relative risk. | 1982 Feb |
|
Occurrence of neuroleptic malignant syndrome in a narcoleptic patient. | 1983 Jun |
|
[Catatonia due to fluphenazine]. | 1986 Apr 1 |
|
A case of neuroleptic malignant syndrome in a mentally retarded adolescent. | 1986 Nov |
|
Drug-induced dystonia in young and elderly patients. | 1988 Jul |
|
Actions of ORG 5222 as a novel psychotropic agent. | 1990 Mar |
|
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. | 1994 Mar |
|
Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist. | 1995 Nov-Dec |
|
Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine. | 1995 Sep 5 |
|
Roxindole, a potential antidepressant. I. Effect on the dopamine system. | 1996 |
|
Tardive dyskinesia induced by risperidone? | 1996 Jun |
|
The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved? | 1999 |
|
Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats. | 1999 Aug 20 |
|
Sexual side effects of novel antipsychotic medications. | 2002 Jul 1 |
|
Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. | 2004 Apr 15 |
|
Invited review: fluphenazine augments retinal oxidative stress. | 2005 Aug |
|
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs. | 2005 May |
|
In silico prediction of pregnane X receptor activators by machine learning approaches. | 2007 Jan |
|
Incorporating clinical guidelines through clinician decision-making. | 2008 Feb 29 |
|
Relapse of tardive dyskinesia due to reduction in clozapine dose. | 2009 Aug |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Patents
Sample Use Guides
For most patients, a dose of 12.5 to 25 mg (0.5 to 1 mL) may be given to initiate therapy.
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8302284
30uM Fluphenazine inhibited the high-threshold Ca2 channel current in rat sympathetic neurons (blocking by 66%).
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4MB4M45MSE
Created by
admin on Sat Dec 16 18:07:35 GMT 2023 , Edited by admin on Sat Dec 16 18:07:35 GMT 2023
|
PRIMARY | |||
|
3093-66-1
Created by
admin on Sat Dec 16 18:07:35 GMT 2023 , Edited by admin on Sat Dec 16 18:07:35 GMT 2023
|
PRIMARY | |||
|
100000089036
Created by
admin on Sat Dec 16 18:07:35 GMT 2023 , Edited by admin on Sat Dec 16 18:07:35 GMT 2023
|
PRIMARY | |||
|
6451517
Created by
admin on Sat Dec 16 18:07:35 GMT 2023 , Edited by admin on Sat Dec 16 18:07:35 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD